"Weight-loss drugs" is an increasingly inadequate label. Between 2024 and 2026, the two flagship GLP-1 molecules accumulated a portfolio of approved indications that reads like a chronic-disease formulary — and because the approvals split unevenly between semaglutide and tirzepatide, the map now genuinely matters when choosing your medication.
| Indication | Semaglutide | Tirzepatide |
|---|---|---|
| Chronic weight management | ✔ Wegovy · oral Wegovy | ✔ Zepbound |
| Type 2 diabetes | ✔ Ozempic · Rybelsus | ✔ Mounjaro |
| Cardiovascular risk reduction | ✔ (SELECT: 20% MACE reduction) | Program maturing |
| Chronic kidney disease (w/ T2D) | ✔ (FLOW trial) | — |
| Metabolic liver disease (MASH) | ✔ (2026 indication) | — |
| Obstructive sleep apnea | — | ✔ (first drug approved for OSA) |
| Heart failure (HFpEF) w/ obesity | Supportive data | Positive trial data (SUMMIT) |
Why the Map Changes Medication Choice
When both drugs only treated weight, tirzepatide's bigger number usually won the comparison. The indication map complicates that in useful ways:
- Cardiac history or high cardiovascular risk? Semaglutide's SELECT evidence — a 20% reduction in major adverse cardiovascular events and a mortality benefit — is protection tirzepatide can't yet claim on-label. For many patients this outweighs an efficacy gap on the scale.
- Kidney disease with diabetes? Semaglutide again, via FLOW.
- Fatty liver disease? The 2026 MASH indication makes semaglutide the first GLP-1 with liver disease on its label — relevant to a very large, mostly undiagnosed population.
- Sleep apnea? Tirzepatide's lane — the first medication ever approved for OSA, and a genuine tiebreaker for the millions with both obesity and apnea.
The Insurance Angle Ex-Weight-Loss
Expanded indications also reshape coverage fights: plans that exclude "weight-loss drugs" often cover the same molecules for cardiovascular, kidney, or diabetes indications. If you carry a qualifying diagnosis, the indication map is prior-authorization ammunition — a conversation worth having with your prescriber before paying cash.
Getting Evaluated With the Full Map in Hand
A prescriber weighing your comorbidities against this map is the whole game now — bring your history, not just your goal weight:
Sesame Care
Brand-name route — Rybelsus, oral Wegovy, and injectable brand GLP-1s via low-cost doctor visits.
Flat-rate visits · brand-name FDA-approved medications only
- FDA-approved brand-name medications only
- Fast video visits in most states
- Pairs well with $199 direct-pay channels
RxSpan MD
Physician-led telehealth program with ongoing dose management.
Program pricing shown at checkout
- Physician-led care
- Ongoing dose management
- US pharmacy fulfillment
Compounded medications are not FDA-approved. They are prepared by licensed pharmacies but have not been evaluated by the FDA for safety, effectiveness, or quality.
Visit RxSpan MD Paid linkEmbody
Injectable semaglutide program and our highest-payout comparison anchor for injection-first shoppers.
Injectable compounded semaglutide — pricing at intake
- Injectable-only program (no oral track)
- Licensed provider consult included
- US pharmacy fulfillment
Compounded medications are not FDA-approved. They are prepared by licensed pharmacies but have not been evaluated by the FDA for safety, effectiveness, or quality.
Visit Embody Paid linkBottom Line
The class that started as diabetes drugs and became weight-loss drugs is ending up as something bigger: metabolic-disease infrastructure. Choose with the whole map, because you're likely buying more protection than the scale shows.
Last updated August 2026. Indication details evolve; confirm current labeling with your provider.
See the Full Comparison Grid
Every provider and channel we track — price, format, and what's included — side by side.
Compare All ProvidersMore Comparisons
Semaglutide vs. Tirzepatide: The Rematch
The 2026 Research Roundup: What New Studies Showed
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. All prescription medications discussed require evaluation by a licensed healthcare provider. Always consult your doctor before starting, stopping, or changing any medication. Individual results vary.
Affiliate Disclosure: CompareGLP-1 may earn a commission when you use links on this page, at no additional cost to you. Links marked "Paid link" are sponsored. Our comparisons are editorially independent — rankings and verdicts are never sold, and we never fabricate statistics, testimonials, or reviews.